Abstract: The present invention relates to substances and compositions thereof useful in the control of cancer stem cell persistence and concomitant tumor recurrence and/or control of tumor growth. In particular, the invention relates to substances and compositions useful in the treatment of cancers and/or tumors linked to cancer stem cells, preferably brain cancers and/or tumors, in a subject.

Abstract: An apparatus for the treatment and/or prevention of corneal diseases includes an applicator head. The applicator head includes a radiation source capable of exciting a non-toxic chromophore. A control is operable to activate the radiation source to radiate, wherein at least one of the following two conditions is met: the applicator head includes a sensor capable of measuring a signal dependent on a position of the applicator head relative to the cornea; or, the applicator head is configured to be in physical contact with the cornea. The control is operable to activate the radiation source to radiate depending on a signal measured by the sensor or to activate the radiation source when the applicator head touches the cornea, respectively.

Abstract: The present invention is a method and apparatus for protection of various items against counterfeiting using physical unclonable features of item microstructure images. The protection is based on the proposed identification and authentication protocols coupled with portable devices. In both cases a special transform is applied to data that provides a unique representation in the secure key-dependent domain of reduced dimensionality that also simultaneously resolves performance-security-complexity and memory storage requirement trade-offs. The enrolled database needed for the identification can be stored in the public domain without any risk to be used by the counterfeiters. Additionally, it can be easily transportable to various portable devices due to its small size. Notably, the proposed transformations are chosen in such a way to guarantee the best possible performance in terms of identification accuracy with respect to the identification in the raw data domain.

Abstract: The present invention is directed to the use of macrocyclic lactones, in particular avermectins, in the treatment of conditions whose formation, occurrence, development or growth is associated with aberrant Wnt signalling in particular the treatment of colorectal cancer.

Abstract: Apparatus for real-time in vivo bioluminescence monitoring in a conscious small animal, comprising a light-tight enclosure (4) with a base (16), side wall (19) and cover (20) configured for housing the small animal such that it may move freely, a bioluminescence detector system (6) comprising a light detector (22) for detecting the light emitted by said small animal connected to a data processing system, and a life sustaining system (8) configured for maintaining the small animal alive for a prolonged period of time spanning from a few days to a few weeks.

Abstract: Methods for the preparation of cell compositions based on fluorescence following excitation at wavelength of or about 488 nm and isolated cell compositions obtained therefrom wherein isolated cells exhibit (i) autofluorescence at or about 520 nm or (ii) absence of fluorescence at or about 520 nm and a positive shift in the fluorescence detected at >630 nm. These methods provide for enrichment of immature or stem cancer-initiating cells from tumors (notably, cancers of the central and peripheral nervous system and metastasis to the brain) and methods for screening antitumor agents using the same. Also provided are methods of detecting immature or stem cancer-initiating cells in a cell sample and methods of detecting recurrence of cancer stem cells in a cancer stem cell sample following treatment with an agent.

Abstract: The invention relates to a method of aiding the diagnosis of acute brain damage in a subject, said method comprising (i) assaying the concentration of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1 in a sample from said subject; and (ii) assaying the concentration of at least one further polypeptide selected from Panel A; (Hi) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for said polypeptides; (iv) wherein a finding of a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in said subject.

Abstract: The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.

Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.

Abstract: Described herein are compositions comprising polymers prepared by melt polycondensation of 2-hydroxyalkyl acids. Methods of making and using the compositions are also disclosed.

Abstract: The present invention is directed to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful for the treatment of a disorder selected from obesity and insulin resistance and related methods and pharmaceutical formulations. In particular, the invention relates to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful in the treatment of metabolic syndrome.

Abstract: The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier.

Abstract: For distributing a sequence of symbols, an emitter station transmits to a receiver station quantum systems through a quantum channel. Each of the quantum systems belongs to a set of at least two non-orthogonal quantum states and comprises a group of at least two weak coherent states of an electromagnetic field. Each weak coherent state is in a time bin of duration t. Centers of neighboring weak coherent states in a group are separated by a time T1, with T1 greater than t. Centers of neighboring weak coherent states in adjacent quantum systems are separated by a time T2, with T2 greater than t. In addition, any two weak coherent states separated by T1+T2 are phase coherent. The receiver station comprises an optical subsystem configured to check, for received quantum systems, phase coherence of two weak coherent states of time bins separated by T1+T2.

Abstract: The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier.

Abstract: The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4+ epitope; and (iii) at least one CD8+ epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases.

Abstract: The present invention is directed to stable protein formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing therapeutic proteins in aqueous solution.

Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).

Abstract: This invention relates to a method for analysis of one or more glycated proteins in a sample, the glycated proteins containing moieties of a natural reducing carbohydrate bound at one or more glycation sites in the proteins, the method comprising: treating the sample with a stable isotopic form of said carbohydrate which is different in mass from the natural carbohydrate, whereby the isotopic form becomes incorporated by glycation in one or more proteins in the sample, and one or more of said proteins are accordingly glycated by the natural reducing carbohydrate and by the isotopic form of the carbohydrate at identical glycation sites; and identifying and/or quantifying the glycated proteins by the difference in mass between the natural carbohydrate and the isotopic form of the carbohydrate at identical glycation sites.

Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.